deltatrials
Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT03425838

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

BOOG 2017-03: Endocrine Therapy Plus CDK 4/6 Inhibition in First- or Second-line for Hormone Receptor Positive Advanced Breast Cancer - the SONIA Study

Sponsor: Borstkanker Onderzoek Groep

Updated 18 times since 2018 Last updated: Sep 18, 2025 Started: Nov 9, 2017 Primary completion: Mar 6, 2023 Completion: Dec 31, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Breast Neoplasm Female and is currently ongoing. Borstkanker Onderzoek Groep leads this study, which shows 18 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Nov 2018 · 3 months · monthly snapshot~Nov 2018 – ~Feb 2019 · 3 months · monthly snapshot~Feb 2019 – ~Jun 2019 · 4 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~May 2022 · 8 months · monthly snapshot~May 2022 – ~Mar 2023 · 10 months · monthly snapshot~Mar 2023 – ~Apr 2023 · 31 days · monthly snapshot~Apr 2023 – ~Sep 2023 · 5 months · monthly snapshot~Sep 2023 – ~Jul 2024 · 10 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshot

Change History

18 versions recorded
  1. Oct 2025 — Present [monthly]

    Active Not Recruiting PHASE3

  2. Sep 2025 — Oct 2025 [monthly]

    Active Not Recruiting PHASE3

  3. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE3

  4. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE3

  5. Sep 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE3

Show 13 earlier versions
  1. Apr 2023 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

  2. Mar 2023 — Apr 2023 [monthly]

    Active Not Recruiting PHASE3

  3. May 2022 — Mar 2023 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  4. Sep 2021 — May 2022 [monthly]

    Recruiting PHASE3

  5. Jan 2021 — Sep 2021 [monthly]

    Recruiting PHASE3

  6. Feb 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  7. Jun 2019 — Feb 2020 [monthly]

    Recruiting PHASE3

  8. Feb 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  9. Nov 2018 — Feb 2019 [monthly]

    Recruiting PHASE3

  10. Aug 2018 — Nov 2018 [monthly]

    Recruiting PHASE3

  11. Jul 2018 — Aug 2018 [monthly]

    Recruiting PHASE3

  12. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE3

  13. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

    First recorded

Nov 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Borstkanker Onderzoek Groep
Data source: Borstkanker Onderzoek Groep

For direct contact, visit the study record on ClinicalTrials.gov .